1. The "Golden Rule" of Documentation
Ref: ACR Revised Guidance (05-22-2024)
The most significant shift in the recent ACR revision isn’t just what you need, but where it is. All qualification documentation must be available on-site for annual inspections. FDA inspectors are issuing Level 3 citations for facilities that cannot produce records immediately during an inspection.[1]
Action Item: Ensure your initial and continuing qualification forms are not just "filed away" at corporate, but accessible at every facility where you interpret.
2. Initial Qualifications (The Barrier to Entry)
Before interpreting your first independent mammogram, you must meet all of the following:
-
Licensure: Valid state license to practice medicine.
-
Certification: Board certified in diagnostic radiology (ABR, AOBR, or RCPSC) OR 3 months of formal mammography training.[1]
-
CME: 60 Category 1 hours in mammography (at least 15 earned within the 3 years prior to qualifying).[1][2]
-
Experience: Interpretation of 240 mammographic exams under supervision within the 6 months prior to qualifying (or within the last 2 years of residency).
3. Maintaining Your Status (Continuing Requirements)
MQSA works on a rolling timeline. You must actively maintain these metrics to avoid falling into "non-compliant" status, which requires a rigorous re-establishment process.
-
Continuing Experience: Interpret 960 mammographic exams every 24 months.
-
Continuing Education (CME): Earn 15 Category 1 CME credits in mammography every 36 months.[1][3][4]
-
New Modalities: Before using a new modality (e.g., DBT/Tomosynthesis) independently, you must complete 8 hours of specific training in that modality.[3][4][5][6][7]
4. The "Gotchas"
-
Multi-Reading: If you are short on volume, "multi-reading" (double reading) exams counts toward your 960 total, but documentation is key.
-
Re-establishment: If you lapse in either CME or experience, you cannot interpret independently until you have completed the FDA-mandated re-establishment protocol.[1] There is no grace period for interpretation.
-
Upcoming Regulation: Be aware that the FDA’s new rule on breast density reporting and outcome audits is effective as of September 10, 2024. While this impacts facility reporting, it directly affects the data interpreting physicians must include in reports.
